| Autor: |
Vanlerberghe J; CHU Lille, Service de Dermatologie, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE), Lille, France., Dezoteux F; CHU Lille, Service de Dermatologie, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE), Lille, France., Martin C; Department of Biostatistics, CHU Lille, Lille, France., Jachiet M; Université de Paris, Faculté de Médecine, AP-HP, Service de Dermatologie, Hôpital Saint-Louis, Paris, France., Soria A; Service de Dermatologie et d'Allergologie, Hôpital Tenon, Paris HUEP, APHP, Paris, France, Sorbonne Universités Paris, Centre d'Immunologie et des Maladies Infectieuses - Paris (Cimi-Paris), INSERM U1135, Paris, France., Tétart F; Department of Dermatology, Inserm U519, Rouen University Hospital, Rouen, France., Modeste-Duval AB; Department of Dermatology, Inserm U519, Rouen University Hospital, Rouen, France., Bursztejn AC; Department of Dermatology, Nancy University Hospital, Nancy, France., Misery L; Department of Dermatology, University Hospital of Brest, Brest, France., Aubin F; Service de Dermatologie, Inserm 1098, Centre Hospitalier Régional Universitaire de Besançon, Université de Franche Comté, Besançon, France., Lasek A; Service de Dermatologie, Hôpital St Vincent de Paul, Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, France., Leleu C; Service de Dermatologie, Hôpital Le Bocage, CHU Dijon, Dijon, France., Du-Thanh A; Service de Dermatologie, CHU Montpellier, PCCI, INSERM, Univ Montpellier, Montpellier, France., Pasteur J; Dermatology Department, University of Clermont-Ferrand, Clermont-Ferrand, France., Pralong P; Dermatology and Allergology Department, Grenoble University Hospital, Grenoble, France., Nosbaum A; Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Pierre Benite, University of Lyon, CIRI (International Center for Infectiology Research), INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France., Droitcourt C; Service de Dermatologie, Centre Hospitalier Universitaire Pontchaillou, UMR_S 1085, Irset (Institut de recherche en santé, environnement et travail), EHESP, Inserm, Université de Rennes, Rennes, France., Viguier M; Department of Dermatology, Hôpital Robert Debré, Université de Reims Champagne-Ardenne and EA 7509 (IRMAIC), Reims, France., Tauber M; Dermatology Department, Toulouse University Hospital and Inserm UMR 1291- CNRS, Infinity (L'Institut Toulousain des Maladies Infectieuses et Inflammatoires), Toulouse, France., Seneschal J; Service de Dermatologie, Centre de Référence des Maladies Rares de la Peau, CNRS UMR 5164, ImmunoConCept, Université de Bordeaux, Hôpital Saint André, CHU de Bordeaux, Bordeaux, France., Barbarot S; Nantes Université, Department of Dermatology, CHU Nantes, UMR 1280 PhAN, INRAE, Nantes, France., Staumont-Sallé D; CHU Lille, Service de Dermatologie, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE), Lille, France. Electronic address: delphine.salle@chu-lille.fr. |
| Abstrakt: |
Competing Interests: Conflicts of interest Dezoteux has been an investigator and a consultant and speaker for AbbVie, Almirall, Eli Lilly, Janssen, Leo Pharma, Novartis and Sanofi-Regeneron. Jachiet has been an investigator and/or a consultant and/or speaker for AbbVie, Eli Lilly, Leo Pharma, Pfizer, Galderma and Sanofi-Regeneron. Soria has been an investigator and/or a consultant and/or speaker for AbbVie, Eli Lilly, Leo Pharma, Novartis, Pfizer and Sanofi-Regeneron. Tétart has been an investigator and/or a speaker and/or consultant for Sanofi-Regeneron. Modeste-Duval has been an investigator and/or a speaker and/or consultant fort Sanofi-Regeneron. Bursztejn has been a consultant and/or speaker for AbbVie, Almirall, Amgen, Eli Lilly, Galderma, Janssen, Leo Pharma, Novartis, Pfizer and Sanofi-Regeneron. Misery has been an investigator and/or a consultant and/or speaker for AbbVie, Almirall, Amgen, Astra-Zeneca, Eli Lilly, Galderma, Leo Pharma, Novartis, Pfizer and Sanofi-Regeneron. Aubin has been an investigator and/or a consultant and/or speaker for AbbVie, Almirall, Amgen, Astra-Zeneca, BMS, Eli Lilly, Galderma, Leo Pharma, MSD, Novartis, Pfizer, Pierre Fabre and Sanofi-Regeneron. Lasek has been an investigator and/or a speaker and/or consultant for Sanofi-Regeneron. Leleu has been an investigator for Leo Pharma, a consultant and/or speaker for AbbVie, Amgen, Eli Lilly, Novartis, and Sanofi-Regeneron. Du-Thanh has been an investigator for Leo Pharma, a consultant and/or speaker for AbbVie, Amgen, Eli Lilly, Novartis, and Sanofi-Regeneron. Pasteur has been an investigator and/or a consultant and/or speaker for AbbVie, Eli Lilly, Leo Pharma, Novartis, Pfizer, and Sanofi-Regeneron. Pralong has been an investigator for Eli Lilly, a speaker for AbbVie, Sanofi-Regeneron. Nosbaum has been an investigator and/or a consultant and/or speaker for AbbVie, Almirall, Amgen, Eli Lilly, Galderma, Leo Pharma, Medac, Novartis, Pfizer and Sanofi-Regeneron. Droitcourt has been an investigator and/or a consultant and/or speaker for AbbVie, Eli Lilly, Leo Pharma, Novartis, Pfizer and Sanofi-Regeneron. Viguier has been an investigator, a consultant and/or speaker for AbbVie, Almirall, Biogen, Galderma, Eli Lilly, Boehringer Ingelheim, Medac, Janssen Cilag and Bristol Myers Squibb. Seneschal has received personal fees from AbbVie, Almirall, Leo Pharma, Eli Lilly, Novartis, Pfizer, Pierre Fabre, Sanofi-Genzyme. Barbarot has been an investigator or a speaker for AstraZeneca, Almirall, Sanofi-Genzyme, AbbVie, Novartis, Janssen, Leo Pharma, Pfizer, Eli Lilly, UCB Pharma, Chiesi. Staumont-Sallé has been an investigator and/or a consultant and/or speaker for AbbVie, Almirall, Amgen, AstraZeneca, Eli Lilly, Galderma, Leo Pharma, Novartis, Pfizer, Janssen and Sanofi-Regeneron. Tauber is a consultant for Abbvie, Eli Lilly, Janssen, Medac and a speaker for Abbvie, Eli Lilly, Janssen and Sanofi. Vanlerberghe and Martin have no conflicts of interest to declare. |
Full Text from ScienceDirect